These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Osimertinib effective in EGFR T790M-positive lung cancer. Mayor S Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430 [No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer. Iwafuchi Y; Saito I; Narita I Ther Apher Dial; 2017 Aug; 21(4):416-417. PubMed ID: 28332292 [No Abstract] [Full Text] [Related]
4. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389 [TBL] [Abstract][Full Text] [Related]
6. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS; N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359 [TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719 [TBL] [Abstract][Full Text] [Related]
8. CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC. Gourd E Lancet Oncol; 2018 Oct; 19(10):e516. PubMed ID: 30197172 [No Abstract] [Full Text] [Related]
9. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid. Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978 [No Abstract] [Full Text] [Related]
10. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737 [TBL] [Abstract][Full Text] [Related]
13. Brigatinib versus crizotinib for ALK-positive NSCLC. Stirrups R Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790 [No Abstract] [Full Text] [Related]
14. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012 [TBL] [Abstract][Full Text] [Related]
16. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Sullivan I; Planchard D Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815 [TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Resected Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS; N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177 [TBL] [Abstract][Full Text] [Related]
19. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244 [No Abstract] [Full Text] [Related]
20. Osimertinib for the treatment of patients with Alsharedi M; Bukamur H; Elhamdani A Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]